Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Nexentis Technologies Inc. Common Stock

NXTS

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.82 – $2.14
Volume 6,980
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$945.46K
Price / earnings
—
Price / book
0.41×
Price / sales
472.73×
EV / sales
-3,127.77×
EV / EBITDA
1.24×

Profitability

Earnings per share
-$36.40
Return on assets
-92.53%
Return on equity
-755.28%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.18×
Current ratio
3.72×
Quick ratio
3.72×
Cash ratio
2.73×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.52M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NXTS, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$0$0
Cost of revenue$0$0
Gross profit$0$0
Selling, general and administrative$1.26M$1.9M
Research and development$373K$275K
Total operating expenses$1.74M$8.57M
Operating income-$1.74M-$8.57M
Interest expense-$8.84M-$100K
Income before taxes-$11.18M-$7.45M
Income taxes-$23K-$23K
Net income-$11.16M-$6.59M
Net income attributable to common shareholders-$11.15M-$6.58M
EBITDA-$1.61M-$2.2M
Basic earnings per share-$68.30-$53.70
Diluted earnings per share-$68.30-$53.70

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis Technologies' subsidiary MitoCareX Bio Ltd. announced the appointment of Prof. Dan T. Major to its Scientific Advisory Board to strengthen its computational drug discovery capabilities. Prof. Major, a computational chemistry expert from Bar-Ilan University, will advise on in silico drug-discovery approaches and computational methods to support MitoCareX's expansion of internal scientific capabilities and prioritization of discovery programs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 9, 20261-for-5reverse split
Apr 8, 20261-for-7reverse split